Contact Information: For further information contact: Fern Lazar/David Carey Lazar Partners Ltd. 1-(866) GIVEN-IR
Given Imaging to Host Third Quarter 2008 Financial Results Conference Calls
| Source: Given Imaging
YOQNEAM, ISRAEL--(Marketwire - October 23, 2008) - Given Imaging (NASDAQ : GIVN ) (TELAVIV : GIVN ), the global leader in capsule endoscopy, today announced that the
company will host conference calls on Wednesday, November 12, 2008 to
discuss third quarter 2008 financial results. The company plans to release
results following the close of trading on Tuesday, November 11, 2008.
The company will host a conference call in English on Wednesday, November
12 at 9:00am ET. To participate in this teleconference, please dial
800-926-7061 fifteen minutes before the conference is scheduled to begin.
Callers outside of the U.S. should dial 913-312-0379. The call will also be
webcast live at www.givenimaging.com. A replay of the call will be
available for two weeks on the company's website, or until November 26,
2008 by dialing 888-203-1112. Callers outside of the U.S. should dial
719-457-0820. The replay participant code is 3443955.
The company will host a separate conference call in Hebrew on November 12
at 14:00 Israel time (7:00am ET). To access this call, please dial
+972-3-9180650 fifteen minutes before the conference is scheduled to begin.
A replay of the call will be available November 12-14 by dialing
+972-3-9255941.
About Given Imaging Ltd.
Given Imaging is redefining gastrointestinal diagnosis by developing,
producing and marketing innovative, patient-friendly products for detecting
gastrointestinal disorders. The company's technology platform is the
PillCam® Platform, featuring the PillCam video capsule, a disposable,
miniature video camera contained in a capsule, which is ingested by the
patient, a sensor array, data recorder and RAPID® software. Given Imaging
markets a number of available capsules: the second-generation PillCam SB 2
video capsule to visualize the entire small intestine which is currently
marketed in the United States and in more than 60 other countries; the
second-generation PillCam ESO 2 video capsule to visualize the esophagus;
the Agile™ patency capsule to determine the free passage of the PillCam
capsule in the GI tract and the PillCam COLON video capsule to visualize
the colon that has been cleared for marketing in the European Union.
PillCam COLON has received a CE Mark, but is not cleared for marketing or
available for commercial distribution in the USA. More than 750,000
patients worldwide have benefited from the PillCam capsule endoscopy
procedure. Given Imaging's headquarters, manufacturing and R&D facilities
are located in Yoqneam, Israel. It has operating subsidiary companies in
the United States, Germany, France, Japan, Australia and Singapore. Given
Imaging's largest shareholders include Elron Electronic Industries (NASDAQ:ELRN) (TELAVIV:ELRN). For more information, visit
http://www.givenimaging.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning
of the "safe harbor" provisions of the U.S. Private Securities Litigation
Reform Act of 1995. These forward-looking statements include, but are not
limited to, projections about our business and our future revenues,
expenses and profitability. Forward-looking statements may be, but are not
necessarily, identified by the use of forward-looking terminology such as
"may," "anticipates," "estimates," "expects," "intends," "plans,"
"believes," and words and terms of similar substance. Forward-looking
statements involve known and unknown risks, uncertainties and other factors
which may cause the actual events, results, performance, circumstances or
achievements of the Company to be materially different from any future
events, results, performance, circumstances or achievements expressed or
implied by such forward-looking statements. Factors that could cause actual
events, results, performance, circumstances or achievements to differ from
such forward-looking statements include, but are not limited to, the
following: (1) our ability to develop and bring to market new products, (2)
our ability to receive regulatory clearance or approval to market our
products or changes in regulatory environment, (3) our success in
implementing our sales, marketing and manufacturing plans, (4) protection
and validity of patents and other intellectual property rights, (5) the
impact of currency exchange rates, (6) the effect of competition by other
companies, (7) the outcome of significant litigation, (8) our ability to
obtain reimbursement for our product from government and commercial payors,
(9) quarterly variations in operating results, (10) the possibility of
armed conflict or civil or military unrest in Israel, and (11) other risks
and factors disclosed in our filings with the U.S. Securities and Exchange
Commission, including, but not limited to, risks and factors identified
under such headings as "Risk Factors," "Cautionary Language Regarding
Forward-Looking Statements" and "Operating Results and Financial Review and
Prospects" in the Company's Annual Report on Form 20-F for the year ended
December 31, 2007. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this press
release. Except for the Company's ongoing obligations to disclose material
information under the applicable securities laws, it undertakes no
obligation to release publicly any revisions to any forward-looking
statements, to report events or to report the occurrence of unanticipated
events.